• Brochures
  • AI digitization
  • September 9, 2026

The First Autonomous Blood Morphology Analyzer

The Evolution of Cell Morphology: Once Manual. Then Digital. Now Autonomous.

Download the brochure

The Complete Blood Count (CBC) is the most frequently ordered lab test in the world, yet its most critical follow-up step — the morphology review — sits in a bottleneck that has not changed in hundreds of years. It remains labor-intensive, expertise-dependent, and variable. With severe staffing shortages, shrinking reimbursements, and rising volumes, labs face an operational crisis.

Scopio's Complete Blood Morphology (CBM®) Analyzer solves this head-on. It autonomously analyzes and reports routine samples, eliminating the need for hands-on morphology review and establishing a new clinical and operational standard for hematology labs worldwide.

Proven in a workflow comparison study¹

Over 85%

of peripheral blood smears autonomously analyzed

resulting in
86%

reduction in total hands-on review time

Read the full workflow comparison study →

Solving the last bottleneck

Automation gaps

Blood smear review still remains a highly manual task in an otherwise automated and standardized lab environment.

Labor shortages

Vacancies, burnout, and long training cycles restrict testing capacity.

Budgetary pressures

System-wide budget cuts demand higher diagnostic output without additional spending.

Result variability

Subjective manual review introduces inconsistency across sites and shifts.

The power of the CBM® Analyzer

Positioned downstream of the CBC analyzer, CBM® delivers autonomous morphology analysis for routine blood smears.

10x more cells. The confidence behind autonomous analysis.

The CBM® Analyzer combines proprietary Full-Field™ imaging and AI to evaluate every sample at an unprecedented scale.

1,000 WBCs

analyzed

10,000 RBCs

analyzed

5x more platelets

analyzed

Analyzing 10x more cells than the current standard delivers the statistical power and sensitivity required to confidently auto-report routine samples.

A new way to run the morphology bench

Autonomous analysis

Leveraging advanced AI that analyzes thousands of cells per sample to auto-report results directly to the LIS.

Process standardization

Replaces subjective variance with statistically robust, reproducible reports across all shifts, sites, and networks.

Workforce optimization

Alleviates hiring pressures, freeing staff to work on higher value tasks and only on the samples that require their expertise.

Advanced diagnostics

Establishes a quantitative foundation for next-generation, morphology-based biomarkers.

Frequently asked questions

Digital morphology systems still require a technologist to review and confirm every sample — they accelerate the bench rather than remove it. CBM® auto-reports routine samples end to end, so trained staff only touch the cases that need their expertise.

1,000 WBCs, 10,000 RBCs, and platelets across 5x more fields of view — roughly 10x more cells than the current diagnostic standard. That scale is what provides the statistical power to auto-report with confidence.

In a workflow comparison study of 225 peripheral blood smears at a US reference laboratory, over 85% were autonomously analyzed and reported, producing an 86% reduction in total hands-on review time.¹

No. It removes routine samples from the review queue and routes flagged cases — blasts, schistocytes, plasma cells — to a morphologist, so expert time goes to the samples that need it.

Yes. Results for auto-reported samples are delivered directly to the LIS.

Not yet. CBM® is still in development and not yet available for in vitro diagnostic use. Pending FDA clearance in the US. Contact our team to discuss early access.

Get the brochure

¹ Workflow study at a US reference laboratory, n=225 peripheral blood smears.

Scopio's CBM® is still in development, not yet available for in vitro diagnostic use. Final outputs may vary based on sample variability and final product design.